- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.05. | Apimeds Pharmaceuticals US, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 05.05. | Apimeds settles disputes, stock to resume trading today | 2 | Investing.com | ||
| APIMEDS PHARMACEUTICALS US Aktie jetzt für 0€ handeln | |||||
| 04.05. | Apimeds Pharmaceuticals US, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 04.05. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.04. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Apimeds Pharmaceuticals US, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 25.03. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 24.03. | Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery | 135 | Business Wire | MATAWAN, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--MindWave Innovations Inc., a Delaware corporation and wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. ("APUS" or the "Company") (NYSE... ► Artikel lesen | |
| 16.03. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.12.25 | Apimeds Pharmaceuticals US, Inc. and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE | 670 | Business Wire | Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced a merger with MindWave Innovations Inc, uniting Apimeds' late-stage, non-opioid pain-management biologic portfolio with MindWave's AI-driven... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARIS LIFE SCIENCES | 14,300 | -1,38 % | Caris Life Sciences Reports First Quarter 2026 Financial Results | Revenue growth of 79% driven by strong performance in molecular profiling services
IRVING, Texas, May 7, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq:... ► Artikel lesen | |
| AKTIS ONCOLOGY | 24,900 | -0,48 % | Aktis Oncology Inc.: Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors | Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingCombined results evaluating AKY-2519 across several B7-H3 expressing tumor types, including... ► Artikel lesen | |
| PARABILIS MEDICINES | 29,550 | 0,00 % | Parabilis Medicines, Inc.: Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | CAMBRIDGE, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) ("Parabilis"), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing... ► Artikel lesen | |
| QIAGEN | 35,965 | -0,55 % | Siemens Energy fällt zurück, Qiagen zieht an: DAX-Ausblick | Der DAX ist nach seinem Rekordlauf in der vergangenen Woche wieder etwas zurückgekommen. Unter dem Strich büßte das größte deutsche Börsenbarometer unter dem Strich mehr als 700 Punkte ein und schloss... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,99 | -0,01 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| ERASCA | 19,160 | -0,05 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| TREVI THERAPEUTICS | 19,075 | +0,03 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| VERA THERAPEUTICS | 38,500 | -1,58 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,060 | +2,95 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,42 | +2,02 % | Piper Sandler reiterates Praxis Precision Medicines stock rating | ||
| KYMERA THERAPEUTICS | 115,77 | +1,56 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,530 | -3,03 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 28,490 | +3,08 % | Mizuho hebt Kursziel für Tango Therapeutics nach vielversprechenden Studiendaten an | ||
| NURIX THERAPEUTICS | 23,120 | 0,00 % | Mizuho hebt Kursziel für Nurix nach Roche-Deal auf 34 US-Dollar an | ||
| ARRIVENT BIOPHARMA | 33,190 | 0,00 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports First Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent... ► Artikel lesen |
APIMEDS PHARMACEUTICALS US INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,660 Euro und damit -2,73 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APIMEDS PHARMACEUTICALS US INC finden Sie auf Wallstreet Online.